A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
NCT ID: NCT06323356
Last Updated: 2025-11-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE3
18 participants
INTERVENTIONAL
2024-03-19
2026-07-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
All participants will be assigned to study treatments of TAK-279 and will be treated with TAK-279 if the participants meet the study rules.
Participants will be in the study for up to 61 weeks including 52 weeks of study treatment. During the study, participants will visit their study clinic for multiple times.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis
NCT06550076
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment
NCT06088043
A Clinical Study of TQH2929 Injection in Treatment With Generalized Pustular Psoriasis (GPP)
NCT06433531
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period
NCT06108544
Study to Assess the Efficacy, Safety and Tolerability of Secukinumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)
NCT01952015
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
TAK-279 for Generalized Pustular Psoriasis
Participants with generalized pustular psoriasis will receive TAK-279 from Day 1 up to Week 52.
TAK-279
Specified drug on specified days.
TAK-279 for Erythrodermic Psoriasis
Participants with erythrodermic psoriasis will receive TAK-279 from Day 1 up to Week 52.
TAK-279
Specified drug on specified days.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
TAK-279
Specified drug on specified days.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Candidate for phototherapy or systemic therapy.
Exclusion Criteria
2. History of recent infection.
3. Any prior exposure to TAK-279, or participation in any study that included a TYK2 inhibitor.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Takeda
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Study Director
Role: STUDY_DIRECTOR
Takeda
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nagoya City University Hospital
Nagoya, Aichi-ken, Japan
Fujita Health University Hospital
Toyoake, Aichi-ken, Japan
Kimitsu Chuo Hospital
Kisarazu, Chiba, Japan
Juntendo University Urayasu Hospital
Urayasu, Chiba, Japan
Hospital of the University of Occupational and Environmental Health, Japan
Kitakyushu, Fukuoka, Japan
Isesaki Municipal Hospital
Isesaki, Gunma, Japan
Kobe University Hospital
Kobe, Hyōgo, Japan
Tokai University Hospital
Isehara, Kanagawa, Japan
Mie University Hospital
Tsu, Mie-ken, Japan
Kansai Medical University Hospital
Hirakata, Osaka, Japan
Saitama Medical University Hospital
Iruma, Saitama, Japan
St.Luke's International Hospital
Chūō, Tokyo, Japan
Teikyo University Hospital
Itabashi-ku, Tokyo, Japan
The Jikei University Hospital
Minato-ku, Tokyo, Japan
Tokyo Medical University Hospital
Shinjuku-ku, Tokyo, Japan
Fukuoka University Hospital
Fukuoka, , Japan
University Hospital, Kyoto Prefectural University of Medicine
Kyoto, , Japan
Okayama University Hospital
Okayama, , Japan
Nippon Life Hospital
Osaka, , Japan
Osaka Metropolitan University Hospital
Osaka, , Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
jRCT2031230714
Identifier Type: REGISTRY
Identifier Source: secondary_id
TAK-279-PsO-3005
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.